Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin O-acyl transferase (GOAT). Compounds of general Formula (I) and substructures thereof, i.e., Formulae (II), (IIa), (IIa1), (IIa2), (IIb), (IIb1), (IIb2), (IIc) and (III), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks GHSr ligand activity that is associated with weight gain and insulin resistance. These and related embodiments will find uses for treating subjects known to have, or suspected of being at risk for having, a condition that would benefit from a decreased level of acylated ghrelin peptide, such as type II diabetes, impaired glucose tolerance, insulin resistance, Prader-Willi syndrome (PWS) and obesity.
公开了与哺乳动物
生长激素释放肽O-酰基转移酶(GOAT)的小分子脂肽类似物
抑制剂有关的组合物和方法。通式(I)及其亚结构,即,通式(II)、(IIa)、(IIa1)、(IIa2)、(IIb)、(IIb1)、(IIb2)、(IIc)和(III)的化合物显示出对
生长激素释放肽的辛酰化反应的强大抑制作用,其中产生的非辛酰化(脱酰基)形式的
生长激素释放肽缺乏与体重增加和
胰岛素抵抗相关的GHSr
配体活性。这些和相关实施例可用于治疗已知或怀疑有患有可能从降低酰化
生长激素释放肽水平中受益的病症的患者,例如II型糖尿病、
葡萄糖耐量受损、
胰岛素抵抗、普拉德-威利综合症(PWS)和肥胖。